Success Metrics

Clinical Success Rate

36.0%

Based on 9 completed trials

Completion Rate

36%(9/25)

Active Trials

0(0%)

Results Posted

22%(2 trials)

Terminated

16(57%)

Phase Distribution

Ph phase_2

11%

Ph phase_3

71%

Ph phase_4

Ph not_applicable

Ph phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution28 total trials

Phase 1Safety & dosage

2(7.1%)

Phase 2Efficacy & side effects

3(10.7%)

Phase 3Large-scale testing

20(71.4%)

Phase 4Post-market surveillance

2(7.1%)

N/ANon-phased studies

1(3.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

34.6%

9 of 26 finished

Non-Completion Rate

65.4%

17 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Terminated(17)

Other(2)

Detailed Status

Terminated16

Completed9

unknown2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

36.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (7.1%)

Phase 23 (10.7%)

Phase 320 (71.4%)

Phase 42 (7.1%)

N/A1 (3.6%)

Trials by Status

unknown27%

completed932%

terminated1657%

withdrawn14%

Recent Activity

0 active trials

Showing 5 of 28

terminatedphase_3

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

NCT00603109

unknownphase_2

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

NCT05622994

completedphase_1

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more

NCT00603109Phase 3

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

Terminated

NCT05622994Phase 2

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Unknown

NCT05398913Phase 1

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Completed

NCT00547118Phase 2

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Terminated

NCT01041170Phase 1

Antagonist-Elicited Cannabis Withdrawal

Completed

NCT00656487Phase 2

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

Completed

NCT00478972Phase 3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

Terminated

NCT00478595Phase 3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Terminated

NCT00299325Phase 3

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

Completed

NCT00228176Phase 3

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

Terminated

NCT00263042Phase 3

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Terminated

NCT00690456Phase 3

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Terminated

NCT00576667Phase 3

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Terminated

NCT00325650Phase 3

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

Terminated

NCT00577148Phase 3

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Terminated

NCT00754689Phase 3

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Withdrawn

NCT00449605Phase 3

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Terminated

NCT00636766Not Applicable

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Completed

NCT00405808Phase 3

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

Terminated

NCT00458081Phase 3

Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 28